News >

Expert Highlights Immunotherapy Success in GU Cancers

Angelica Welch
Published: Thursday, Mar 15, 2018

Ani S. Balmanoukian, MD

Ani S. Balmanoukian, MD
The landscape of genitourinary (GU) malignancies is rapidly evolving, with promising immunotherapy breakthroughs in renal cell carcinoma (RCC) and urothelial carcinoma.

State of the Science Summit™ on Genitourinary Cancers. In an interview during the meeting, she highlighted the focal points of her presentation.

OncLive: Please give an overview of your lecture on advances with immunotherapy in GU cancers.

Balmanoukian: The field has come a long way since the initial introduction of checkpoint inhibitors a few years ago. There have been significant advancements in checkpoint inhibitors in the last 2 years in both RCC and urothelial carcinoma. At the 3-year mark, we are seeing significant differences and improvements in median OS with nivolumab versus everolimus in RCC. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication